133.7 to 210.3 cases per 100 000 population [2] [3] [4] [5] . The problem of STBI treatment is not only a medical issue, but a social problem as well [2] [3] [4] . In the USA the costs of treating one patient with this pathology amount to more than 150 000 USD, and if further rehabilitation is considered, the costs rise to 2 million USD. In the United States approx. 5.3 million people are disabled due to STBI and in EU countries the number is 7.7 million [2] [3] [4] .
Among the complications of STBI, lung injury has a prominent role. It develops in 70-80% of STBI patients, and is one of the factors contributing to the deterioration of the patient's status, with further negative treatment results [4] . Morphological changes in the lungs are detected in 95-97.7% of STBI cases [4] . The most frequent cause of patient mortality on the 3 rd through 5 th day of STBI is acute respiratory distress syndrome (ARDS) [2] , which occurs in 80% of STBI patients with multiple organ failure. Despite the fast development of medical technologies, over the past 20 years there has been a reduction in ARDS patients' mortality [6] . The treatment of ARDS entails the use of expensive medical equipment and drugs, resulting in major costs, averaging from 80 000 USD to 320 000 USD per patient [7] .
Respiratory support is a vital technique for temporary compensation of breathing function [8] , but it is not always adequate in cases of severe respiratory dysfunction, even with the use of up-to-date respiratory technologies [20] .
There have been many attempts to use corticosteroids (CS) for the treatment of ARDS [9] [10] [11] [12] [13] . Randomized clinical trials showed the effectiveness of CS usage for the treatment of ARDS [10] [11] [12] [13] , but the majority of current research indicates that corticosteroids are ineffective or even harmful in ARDS cases [14] . There are also research results that show the inexpediency of CS use in cases of STBI [15] . It can be stated that CS treatment is harmful in STBI followed by ARDS, but it is obligatory to take into consideration that the vast majority of these patients also suffer from severe sepsis [4] . CS are indicated for the treatment of severe sepsis in cases of unstable hemodynamics [21] . That means that STBI patients with severe sepsis and ARDS can take CS when there is a decline in hemodynamics. The question that arises is how it will influence the treatment results. The aim of this study was to find a possible answer to this question.
Material and Methods
The present study is a retrospective analysis of treatment results in patients (n = 267) with STBI followed by severe sepsis and ARDS, who were treated in Ternopil University Hospital (Ternopil, Ukraine) between 2008 and 2014. The development of severe sepsis was followed by unstable hemodynamics in almost all the cases. The instability was corrected by administering adrenomimetic drugs and additional infusion of fluids aimed at achieving stable blood pressure. The most frequent complication during the correction was a rise in blood pressure followed by tachycardia. In order to deal with this, stress doses of Solu-Medrol ® (Pfizer Manufacturing Belgium NV, Puurs, Belgium) were used: 500 mg/day for 3 days, followed by reductions in dosage by onehalf every 3 days. The treatment results were evaluated in relation to the type of respiratory support and presence or absence of CS in complex therapy. The results were evaluated separately for living and dead patients. As the criteria of treatment effectiveness, the duration of mechanical ventilation was used. Two ventilation modes were involved: forced ventilation with controlled volume; and ventilation with two phases of positive pressure in the airway, known as biphasic positive airway pressure (BiPAP, equivalent to pressure-support ventilation or PSV). For the volume-controlled ventilation the Bryz ventilation device (Kyiv State Enterprise "Burevisnyk", Kyiv, Ukraine) was used. For BiPAP ventilation the Draeger Carina ventilator was used (Draeger Medical GmbH, Lübeck, Germany).
During the period from 2008 to 2014, 1120 patients with STBI were treated at Ternopil University Hospital. Severe sepsis developed in 325 of the patients (29.01%); 267 patients (82.15%) with STBI followed by severe sepsis also suffered from ARDS, which necessitated mechanical ventilation. ARDS diagnoses were established on the basis of the Berlin criteria [22] . Among the patients with STBI, severe sepsis and ARDS, the number of people who died was 152 (46.7%).
For the statistical analysis, nonparametric methods were used. The hypothesis about the equality of averages was verified using the Mann-Whitney test. Averages and standard errors were calculated. A p-value under 0.001 was treated as statistically significant. The analysis was carried out using STA-TISTICA v. 10 software (StatSoft Inc., Tulsa, USA).
Results
The patient mortality rate depended on the type of mechanical ventilation used; mortality decreased by 1.24 times when BiPAP mechanical ventilation was used, as opposed to volume-controlled forced ventilation of 5-7 mL/kg. The dead patients who had had forced ventilation with volume control lived for a shorter time than patients on BiPAP ventilation (p = 0.01). Among the patients who survived, the duration of BiPAP ven-tilation was 1.32 times shorter than the duration of forced ventilation with volume control.
With both ventilation modes, the use of CS decreased the mortality rate and reliably had a positive influence on the ventilation period. In dead patients it prolonged the ventilation period (in ACV mode: p = 0.000001; in ВiРАР mode: p = 0.004674). In the surviving patients the converse was true: the ventilation period was shortened (in forced ventilation mode: p = 0.000880; in ВiРАР mode: p = 0.006203).
Discussion
Despite the view that CS usage in case of STBI and ARDS has negative effects [15] , there have been clinical trials that proved the positive effect of CS therapy in such patients. In particular, there are some data about the effectiveness of CS based on a reduction in fibrosis activity [12] . Meduri [10, 11, 13] stated that CS use in ARDS reduces leukocyte extravasation, inhibits leukocyte adhesion to endotheliocytes, increases lymphocyte migration from blood circulation to lymphoid tissue, stops macrophage activity and phagocytosis, stops production of interleukin-1, stops expression of cyclooxygenase-2, stops prostaglandin synthesis and also slows down the fever reaction.
The data from the present study also confirms the experience of Ternopil University Hospital during the treatment of patients with the H1N1 influenza virus epidemic in 2009. At that time, 26 patients with flu entered the anesthesiology and intensive care unit within 12 days. In all of these patients the disease was complicated by the development of ARDS. All 26 patients were put on low volume (5-6 mL/kg) mechanical ventilation with volume control. This group of patients died within 3-4 days, after which this mode of ventilation was no longer given. Instead, ARDS patients got BiPAP ventilation with stress doses of CS, and patient life expectancy considerably increased. Even the patients who died had longer survival period, which increased from 3-4 days to 7-10 days. Approximately 50% of the patients that got ventilation in BiPAP mode along with stress doses of CS survived. The total number of flu patients who got ARDS was 80.
The number of cases observed in 2009 was too low to form judgments about the treatment results depending on the type of respiratory support and CS prescription. But based on that experience and the results of the present study the authors have come to the conclusion that stress doses of CS therapy are effective in flu patients followed by ARDS. Additionally, at the beginning of the flu epidemics in the autumn of 2009, CS treatment was not prescribed, based on research pointing to the harmfulness of CS in ARDS [17, 18] . Later, there were also some publications that indicated the harmfulness of CS for treating the flu [19] .
The present authors are convinced that the results of this research reveal that there is no final verdict about the effectiveness of CS therapy in cases of STBI followed by severe sepsis and ARDS. The presence of severe sepsis may be an important indication for using CS treatment. Further research analyzing the treatment results of such patients in other clinics is needed. BiPAP is equivalent to pressure-support ventilation (PSV); +k -with corticosteroid treatment; p -probability calculated according to the relevant value (dead or alive) in the previous column.
